| 05/03/25 | 15:00:01 | 5 Mar 2025 | | Director/PDMR Shareholding | RNS |
| 03/03/25 | 15:00:00 | 3 Mar 2025 | | Total Voting Rights | RNS |
| 03/03/25 | 07:00:04 | 3 Mar 2025 | | Imfinzi recommended for EU approval for AEGEAN | RNS |
| 28/02/25 | 13:00:00 | 28 Feb 2025 | | Enhertu recommended in EU in post-ET breast cancer | RNS |
| 26/02/25 | 07:00:05 | 26 Feb 2025 | | Camizestrant improved PFS in 1L HR+ breast cancer | RNS |
| 19/02/25 | 07:00:06 | 19 Feb 2025 | | Filing of Form 20-F with SEC | RNS |
| 18/02/25 | 14:00:00 | 18 Feb 2025 | | Holding(s) in Company | RNS |
| 18/02/25 | 11:00:00 | 18 Feb 2025 | | Annual Financial Report | RNS |
| 18/02/25 | 07:00:07 | 18 Feb 2025 | | Directorate Change | RNS |
| 06/02/25 | 07:00:04 | 6 Feb 2025 | | Final Results | RNS |
| 03/02/25 | 17:00:00 | 3 Feb 2025 | | Total Voting Rights | RNS |
| 03/02/25 | 07:00:03 | 3 Feb 2025 | | Imfinzi recommended for EU approval for LS-SCLC | RNS |
| 28/01/25 | 07:00:07 | 28 Jan 2025 | | Enhertu approved in US for breast cancer post ET | RNS |
| 20/01/25 | 07:00:04 | 20 Jan 2025 | | Dato-DXd approved in US for HR+ breast cancer | RNS |
| 17/01/25 | 07:00:04 | 17 Jan 2025 | | Calquence combination approved in US for 1L MCL | RNS |
| 02/01/25 | 15:00:01 | 2 Jan 2025 | | Total Voting Rights | RNS |
| 24/12/24 | 07:00:04 | 24 Dec 2024 | | Dato-DXd NSQ NSCLC application withdrawn in EU | RNS |
| 23/12/24 | 07:00:05 | 23 Dec 2024 | | Tagrisso approved in EU based on LAURA trial | RNS |
| 16/12/24 | 07:00:06 | 16 Dec 2024 | | Directorate Change | RNS |
| 05/12/24 | 07:00:22 | 5 Dec 2024 | | Imfinzi approved in US for limited-stage SCLC | RNS |
| 04/12/24 | 13:45:00 | 4 Dec 2024 | | AstraZeneca appoints Iskra Reic EVP International | RNS |
| 02/12/24 | 15:05:00 | 2 Dec 2024 | | Block listing Interim Review | RNS |
| 02/12/24 | 15:00:00 | 2 Dec 2024 | | Total Voting Rights | RNS |
| 25/11/24 | 07:00:03 | 25 Nov 2024 | | Truqap improved rPFS in advanced prostate cancer | RNS |
| 20/11/24 | 16:00:00 | 20 Nov 2024 | | Director/PDMR Shareholding | RNS |
| 18/11/24 | 07:00:03 | 18 Nov 2024 | | Tagrisso recommended for EU approval - LAURA | RNS |
| 15/11/24 | 14:00:00 | 15 Nov 2024 | | Director/PDMR Shareholding | RNS |
| 15/11/24 | 10:00:00 | 15 Nov 2024 | | Director/PDMR Shareholding | RNS |
| 13/11/24 | 16:00:00 | 13 Nov 2024 | | Director/PDMR Shareholding | RNS |
| 12/11/24 | 07:10:04 | 12 Nov 2024 | | AstraZeneca invests $3.5 billion in US | RNS |
| 12/11/24 | 07:05:00 | 12 Nov 2024 | | KOMET Phase III trial met primary endpoint | RNS |
| 12/11/24 | 07:00:07 | 12 Nov 2024 | | 9M and Q3 2024 Results | RNS |
| 12/11/24 | 07:00:06 | 12 Nov 2024 | | Dato-DXd new BLA submitted, NSQ BLA withdrawn | RNS |
| 08/11/24 | 07:00:08 | 8 Nov 2024 | | Tezspire nasal polyps trial met primary endpoints | RNS |
| 05/11/24 | 16:49:43 | 5 Nov 2024 | | AZN share price movement | RNS |
| 01/11/24 | 15:00:00 | 1 Nov 2024 | | Total Voting Rights | RNS |
| 30/10/24 | 13:00:00 | 30 Oct 2024 | | AZN China President under investigation | RNS |
| 21/10/24 | 07:00:04 | 21 Oct 2024 | | Wainzua recommended for approval in the EU | RNS |
| 07/10/24 | 09:30:00 | 7 Oct 2024 | | AstraZeneca licenses lipid lowering Lp(a) asset | RNS |
| 01/10/24 | 15:00:00 | 1 Oct 2024 | | Total Voting Rights | RNS |
| 26/09/24 | 07:00:13 | 26 Sept 2024 | | Tagrisso US approval in unresectable lung cancer | RNS |
| 23/09/24 | 07:05:01 | 23 Sept 2024 | | Fasenra recommended for EU approval in EGPA | RNS |
| 23/09/24 | 07:00:07 | 23 Sept 2024 | | Final OS results reported for TROPION-Breast01 | RNS |
| 20/09/24 | 18:00:00 | 20 Sept 2024 | | FluMist approved for self-administration in US | RNS |
| 18/09/24 | 07:00:07 | 18 Sept 2024 | | Fasenra EGPA US FDA approval | RNS |
| 13/09/24 | 15:15:00 | 13 Sept 2024 | | Director/PDMR Shareholding | RNS |
| 02/09/24 | 15:00:00 | 2 Sept 2024 | | Total Voting Rights | RNS |
| 16/08/24 | 07:00:06 | 16 Aug 2024 | | Imfinzi approved in US for resectable lung cancer | RNS |
| 01/08/24 | 15:00:01 | 1 Aug 2024 | | Total Voting Rights | RNS |
| 30/07/24 | 07:00:07 | 30 Jul 2024 | | AstraZeneca prices a €1.4bn bond offering | RNS |
